Growth Hormone Secretagogues: CJC-1295, Ipamorelin, GHRP-6, and the Science of GH Release

Growth hormone secretagogues (GHSs) are peptides that stimulate your pituitary gland to release growth hormone. They fall into two categories: GHRH analogs like CJC-1295 and Tesamorelin that amplify GH pulses, and GHRPs like Ipamorelin, GHRP-6, and GHRP-2 that trigger GH release through the ghrelin receptor. When used together, these two pathways produce GH pulses 3–5 times larger than either peptide alone.

Unlike synthetic growth hormone injections that bypass natural regulation, secretagogues work with your body's existing feedback loops. The pituitary still controls how much GH gets released. This distinction matters for safety, side effect profiles, and long-term sustainability.

This guide covers the two mechanistic pathways, profiles of each major secretagogue, why stacking works, and which compounds fit different research contexts.

What Is a Growth Hormone Secretagogue?

A growth hormone secretagogue is any compound that causes the pituitary gland to secrete growth hormone. The term covers both synthetic peptides and small-molecule drugs that interact with receptors involved in GH regulation.

The category emerged from 1970s research into hypothalamic hormones. Scientists discovered that the hypothalamus produces growth hormone-releasing hormone (GHRH), which signals somatotroph cells in the pituitary to release stored GH. Later, researchers identified a second pathway through the ghrelin receptor that could independently trigger GH secretion.

Today, the GHS category includes:

• GHRH analogs: Synthetic versions of natural GHRH with modifications for stability and half-life
• GHRPs: Small peptides (5-6 amino acids) that activate the ghrelin receptor
• Ghrelin mimetics: Oral compounds like MK-677 that also activate the ghrelin receptor

All of these stimulate endogenous GH production rather than replacing it. The pituitary remains in control, and natural feedback mechanisms stay intact.

How Does Pulsatile GH Release Work?

Your body doesn't release growth hormone in a steady stream. Instead, GH comes out in pulses, with the largest spike occurring about an hour after you fall asleep.

This pulsatile pattern emerges from the interplay between two hypothalamic signals:

GHRH (Growth Hormone-Releasing Hormone): Produced by neurons in the arcuate nucleus, GHRH travels through the hypophyseal portal system to reach the anterior pituitary. It binds to receptors on somatotroph cells and triggers GH release through the cAMP signaling pathway.

Somatostatin (GHIH): Produced by neurons in the periventricular nucleus, somatostatin inhibits GH release. It acts as a brake on the system, and its withdrawal allows GH pulses to occur.

According to research published in the American Journal of Physiology, pulses account for over 85% of 24-hour GH release in healthy individuals. The body modulates GH output by changing pulse size rather than pulse frequency.

When somatostatin levels drop, GHRH can trigger a burst of GH from the pituitary. When somatostatin rises again, the pulse ends. This on-off cycling creates the characteristic pulsatile pattern.

GHRPs add a third element. They suppress somatostatin while simultaneously activating pituitary ghrelin receptors. This dual action explains why GHRH and GHRP combinations produce larger GH pulses than either alone.

What Is the Difference Between GHRH and GHRP?

GHRH analogs and GHRPs both increase GH output, but through different receptors and signaling mechanisms.

GHRH Pathway

GHRH analogs bind to the GHRH receptor (GHRHR), a class B G protein-coupled receptor found on pituitary somatotrophs. Binding activates adenylyl cyclase, increases intracellular cAMP, and activates protein kinase A. This cascade opens calcium channels and triggers GH vesicle release.

GHRH analogs include:

• Sermorelin: The first 29 amino acids of native GHRH
• CJC-1295 (with or without DAC): Modified GHRH with extended half-life
• Tesamorelin: FDA-approved GHRH analog with N-terminal modification

These compounds amplify existing GH pulses. They work best when somatostatin tone is low, meaning timing matters.

GHRP Pathway

GHRPs bind to the growth hormone secretagogue receptor 1a (GHS-R1a), also known as the ghrelin receptor. This activates phospholipase C, releases intracellular calcium from IP3-sensitive stores, and triggers GH secretion through a mechanism independent of GHRH.

GHRPs also act at the hypothalamic level, where they suppress somatostatin release and may enhance GHRH secretion. This creates a more permissive environment for GH pulses.

GHRPs include:

• Ipamorelin: Highly selective, minimal cortisol/prolactin effects
• GHRP-6: Potent but increases appetite, cortisol, and prolactin
• GHRP-2: Moderate selectivity, less hunger than GHRP-6
• Hexarelin: Most potent, significant cortisol/prolactin elevation, cardiac receptor activity

The fundamental difference: GHRH analogs enhance pulse amplitude, while GHRPs can initiate pulses and remove inhibitory brakes. Used together, they cover both sides of the equation.

Why Do GHRH and GHRP Combinations Work Better?

When you combine a GHRH analog with a GHRP, the GH response exceeds what either compound produces alone. Research published in the American Journal of Physiology quantified this: combined administration produces GH pulses 3–5 times larger than either peptide solo.

A separate study found that GHRP-2 synergizes with GHRH to augment the latter's effect by 2.2-fold on average.

The synergy occurs because the compounds hit different parts of the same regulatory system:

1. GHRP suppresses somatostatin, removing the inhibitory brake
2. GHRP activates pituitary ghrelin receptors, priming somatotrophs
3. GHRH then amplifies the signal through its own receptor pathway

Neither pathway interferes with the other. If anything, GHRP prepares the pituitary to respond more vigorously to GHRH.

Research also identified factors that affect how much synergy you get. A study examining determinants of GHRH-GHRP synergy found that abdominal visceral fat, IGF-I levels, and IGFBP-3 together explained 60% of the variability in synergistic response. Younger individuals with less visceral fat and higher baseline IGF-I levels showed stronger combination effects.

CJC-1295: The Long-Acting GHRH Analog

CJC-1295 is a synthetic GHRH analog developed to overcome the short half-life of native GHRH (measured in minutes). It exists in two forms:

CJC-1295 without DAC (Modified GRF 1-29): A 29-amino-acid peptide with four amino acid substitutions that resist enzymatic degradation. Half-life is approximately 30 minutes, allowing for pulsatile dosing that mimics natural GH release.

CJC-1295 with DAC (Drug Affinity Complex): The same peptide attached to a lysine linker that binds albumin in the bloodstream. This extends the half-life to 5.8–8.1 days.

Clinical research published in the Journal of Clinical Endocrinology & Metabolism examined CJC-1295 in healthy adults. After a single injection, GH concentrations increased 2- to 10-fold for 6 days or more. IGF-I levels rose 1.5- to 3-fold for 9–11 days. With multiple doses, IGF-I remained elevated above baseline for up to 28 days.

The DAC version provides sustained GH elevation but blunts pulsatility. Researchers studying GH pulse dynamics typically prefer the non-DAC version, which allows for physiological pulse patterns when combined with a GHRP.

No serious adverse reactions were reported in clinical trials at doses of 30–60 μg/kg. CJC-1295 is not FDA-approved for therapeutic use.

Ipamorelin: The Selective GHRP

Ipamorelin, developed by Novo Nordisk in the late 1990s, represents the selectivity end of the GHRP spectrum. This pentapeptide releases GH without significantly affecting cortisol, prolactin, ACTH, or other pituitary hormones.

Research published in the European Journal of Endocrinology demonstrated this selectivity. Ipamorelin did not release ACTH or cortisol at levels significantly different from GHRH stimulation, even at doses more than 200-fold higher than the ED50 for GH release. In contrast, GHRP-6 and GHRP-2 both elevated ACTH and cortisol at equivalent GH-releasing doses.

Pharmacokinetic studies show ipamorelin has a terminal half-life of approximately 2 hours. GH peaks around 40 minutes after administration and returns to baseline within 6 hours.

A Phase 2 clinical trial evaluated ipamorelin for postoperative ileus (ClinicalTrials.gov NCT00672074). The study found that 0.03 mg/kg twice daily for up to 7 days was well tolerated, though it did not impact clinical outcomes for that indication.

Ipamorelin's selectivity makes it popular for protocols where cortisol and prolactin elevation would be problematic. The trade-off is somewhat lower peak GH release compared to less selective GHRPs like Hexarelin.

GHRP-6 and GHRP-2: The Originals

GHRP-6 (Growth Hormone-Releasing Hexapeptide) was among the first synthetic GHRPs developed. It binds the ghrelin receptor (GHS-R1a) and also interacts with CD36 receptors, which contributes to its pronounced appetite stimulation.

The most consistent side effect of GHRP-6 is intense hunger. Research shows GHRP-6 stimulates food intake more potently than any other GHRP. Approximately 70–80% of subjects experience significant appetite increase within 30–60 minutes of administration.

GHRP-6 also elevates cortisol and prolactin in a dose-dependent manner. For researchers studying GH dynamics in isolation, this creates confounding variables.

GHRP-2 (Pralmorelin) was developed as a more selective alternative. It produces slightly higher peak GH at equivalent doses compared to GHRP-6, and the appetite signal is milder. GHRP-2 still raises cortisol and prolactin, but less dramatically than GHRP-6.

GHRP-6 has accumulated more research on tissue-protective effects, particularly in cardiac ischemia-reperfusion models. Cuban and international research groups have documented its activity through the CD36 receptor. Whether this translates to clinical cardiology applications remains to be established.

Both peptides remain popular in research settings. GHRP-6 finds use when appetite stimulation is desirable (such as in wasting conditions), while GHRP-2 suits protocols where the researcher wants GH release with fewer metabolic side effects.

Hexarelin: Maximum Potency, Minimum Selectivity

Hexarelin produces the highest GH release of any GHRP, but this comes with significant cortisol and prolactin elevation. It sits at the opposite end of the selectivity spectrum from Ipamorelin.

What distinguishes Hexarelin is its cardiac receptor activity. Research published in the journal Growth Hormone & IGF Research identified a non-GHSR mechanism: Hexarelin binds CD36 receptors in cardiac tissue, producing cardioprotective effects independent of GH release.

In vitro studies show Hexarelin protects cardiomyocytes from ischemia-reperfusion injury. In human volunteers, acute intravenous administration increased left ventricular ejection fraction (70.7% vs. 64.0%, p < 0.03) without affecting blood pressure or heart rate.

This cardiac activity makes Hexarelin relevant for cardiovascular research, though current evidence comes primarily from animal models and small human studies. Clinical trials for human cardiac applications have not been completed.

Hexarelin also desensitizes faster than other GHRPs. Researchers typically cycle it rather than using continuous protocols.

Tesamorelin: The FDA-Approved GHRH

Tesamorelin is the only FDA-approved growth hormone secretagogue. Approved in 2010 under the brand name Egrifta, it carries an indication for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

The peptide is a 44-amino-acid GHRH analog with a trans-3-hexenoic acid group attached to the N-terminus. This modification protects against degradation by DPP-IV, the enzyme that rapidly breaks down native GHRH.

Phase III clinical trials demonstrated a 15–18% reduction in visceral adipose tissue (VAT) over 26 weeks of treatment. The peptide also improved body image scores in HIV lipodystrophy patients.

In March 2025, the FDA approved a new formulation (Tesamorelin F8) that requires only weekly reconstitution instead of daily preparation, reducing patient burden.

Research beyond the approved indication shows potential in NAFLD/NASH. Clinical trials in HIV patients with fatty liver disease found tesamorelin reduced hepatic fat content and prevented progression of inflammation and fibrosis.

Studies in non-HIV populations have examined effects on cognitive function, with some evidence of improvements in executive function and verbal memory. These applications remain investigational.

Common side effects include joint pain, injection site reactions, and peripheral edema.

MK-677 (Ibutamoren): The Oral Option

MK-677 is not a peptide. It's a small-molecule ghrelin mimetic that can be taken orally, making it unique among GH secretagogues.

Clinical trials demonstrate that MK-677 increases pulsatile GH secretion in older adults to levels observed in young adults. A 2-year randomized controlled trial in 65 healthy adults (ages 60-81) found that subjects taking MK-677 gained 1.1 kg of fat-free mass, while placebo subjects lost 0.5 kg.

At a 25 mg dose, MK-677 increased 24-hour GH concentration by 97% and elevated IGF-I levels by 88% at 4 weeks. The compound produces sustained effects with daily oral dosing.

Research also examined MK-677 for Alzheimer's disease, based on the hypothesis that IGF-1 might slow disease progression. A 12-month trial in 563 patients found no clinical benefit for AD outcomes.

Side effects include elevated prolactin (unlike Ipamorelin), increased fasting glucose, and mild insulin resistance. The insulin effects appear to be clinically insignificant in most studies but warrant monitoring in insulin-resistant individuals.

MK-677 is not FDA-approved. It appears on WADA's prohibited list for athletic competition.

Which Secretagogue for Which Goal?

Different GH secretagogues suit different research contexts:

For GH pulse research with minimal confounding: Ipamorelin + CJC-1295 (without DAC). The selectivity of Ipamorelin avoids cortisol/prolactin effects, while non-DAC CJC-1295 preserves pulsatile dynamics.

For maximum GH output: Hexarelin + CJC-1295 (with DAC). Hexarelin produces the highest peak GH, and DAC-modified CJC-1295 provides sustained elevation. Expect significant cortisol and prolactin elevation.

For appetite stimulation: GHRP-6, alone or combined with GHRH. The strong ghrelin receptor activation produces reliable hunger responses.

For cardiac research: Hexarelin. The CD36 receptor activity in cardiac tissue is not replicated by other GHRPs.

For oral administration: MK-677. It's the only orally bioavailable option, though it lacks the selectivity of Ipamorelin.

For clinical/regulated use: Tesamorelin. It's the only FDA-approved option, though limited to HIV lipodystrophy.

Safety and Regulatory Status

Growth hormone secretagogues fall into a regulatory gray area. Tesamorelin is the only FDA-approved compound in the category. All others are either investigational drugs or research chemicals.

The FDA has issued guidance documents addressing several GH secretagogues in the context of compounding pharmacy regulations. CJC-1295 and Ipamorelin appeared in 2024 nomination documents related to bulk drug substance categories.

Available safety data comes primarily from short-term clinical trials:

• Ipamorelin: Well tolerated in Phase 2 trials up to 7 days
• CJC-1295: No serious adverse events at doses of 30–60 μg/kg in trials lasting up to 49 days
• MK-677: 2-year trial showed generally good tolerability with elevated prolactin and glucose as notable effects
• GHRP-6/GHRP-2: Limited systematic safety data; cortisol and appetite effects are well documented

Long-term safety data are limited for most compounds. Questions remain about chronic effects on glucose metabolism, cancer risk (given IGF-1's role in cell proliferation), and cardiovascular outcomes.

All GH secretagogues appear on WADA's prohibited list for competitive athletes.

Important: This content is for informational purposes only and is not medical advice. Consult a healthcare provider before using any peptides. Most GH secretagogues are not approved for human therapeutic use.

Frequently Asked Questions

What is the difference between GH and GH secretagogues?

Growth hormone (GH) is the hormone itself, a 191-amino-acid protein produced by the pituitary gland. GH secretagogues are compounds that stimulate the pituitary to release its own GH. Injecting synthetic GH bypasses natural regulation and suppresses endogenous production. Secretagogues work with the body's feedback systems, allowing the pituitary to maintain control over GH output.

Can you take GHRH and GHRP at the same time?

Yes. Combining GHRH and GHRP produces synergistic effects, with GH pulses 3–5 times larger than either compound alone. The two pathways use different receptors (GHRHR and GHS-R1a) and signaling mechanisms, so they amplify rather than compete with each other.

Which GHRP has the fewest side effects?

Ipamorelin is the most selective GHRP, releasing GH without significantly elevating cortisol, prolactin, or ACTH. This selectivity comes with somewhat lower peak GH release compared to Hexarelin or GHRP-6.

Is MK-677 a peptide?

No. MK-677 (ibutamoren) is a small-molecule drug that mimics ghrelin's effects at the GHS-R1a receptor. Unlike peptides, it survives the digestive system and can be taken orally.

Why does GHRP-6 make you hungry?

GHRP-6 activates the same receptor as ghrelin, the "hunger hormone." It also binds CD36 receptors involved in appetite regulation. This dual activation produces intense hunger in 70–80% of users within 30–60 minutes of administration.

Are GH secretagogues legal?

Regulatory status varies by country and context. Tesamorelin is FDA-approved for HIV lipodystrophy. Other secretagogues are sold as research chemicals or through compounding pharmacies. All appear on WADA's prohibited list for athletes. Check local regulations before purchasing or using any GH secretagogue.

Conclusion

Growth hormone secretagogues offer a mechanistically distinct approach to GH modulation compared to direct hormone replacement. The two major pathways, GHRH and GHRP, target different receptors and signaling cascades. Their combination produces synergistic effects that neither achieves alone.

Individual secretagogues vary in selectivity, potency, half-life, and side effect profiles. Ipamorelin provides GH release with minimal hormonal disruption. GHRP-6 and Hexarelin sacrifice selectivity for greater potency. CJC-1295 extends the duration of GHRH signaling. Tesamorelin offers an FDA-approved option for a specific indication.

Current evidence comes primarily from short-term studies. Long-term safety data, optimal dosing regimens, and effects of chronic use remain areas for further research.

Sources

• Prolonged Stimulation of Growth Hormone by CJC-1295 - Journal of Clinical Endocrinology & Metabolism
• Ipamorelin, the First Selective Growth Hormone Secretagogue - European Journal of Endocrinology
• Determinants of GHRH and GHRP Synergy in Men - American Journal of Physiology
• The Safety and Efficacy of Growth Hormone Secretagogues - PMC Review
• Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Development - JCSM Rapid Communications
• Differential Pulsatile Secretagogue Control of GH Secretion - American Journal of Physiology
• The Cardiovascular Action of Hexarelin - Growth Hormone & IGF Research
• Effects of MK-677 on Body Composition in Healthy Older Adults - Annals of Internal Medicine
• Physiology, Somatostatin - StatPearls/NCBI
• Tesamorelin FDA Prescribing Information - FDA